This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should Invesco Dividend Achievers ETF (PFM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for PFM
Is Oshares U.S. Quality Dividend ETF (OUSA) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for OUSA
Johnson & Johnson (JNJ) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $159.58 in the latest trading session, marking a +0.23% move from the prior day.
Xencor (XNCR) Inks Deal With J&J for B-Cell Malignancy Treatment
by Zacks Equity Research
Xencor (XNCR) partners will J&J (JNJ) to develop and commercialize bispecific antibody candidates against B-cell malignancy. Resultantly, the stock gains.
Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV
by Zacks Equity Research
Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Alibaba, Netflix, Qualcomm and Enbridge
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Alibaba, Netflix, Qualcomm and Enbridge
Top Analyst Reports for Johnson & Johnson, Alibaba & Netflix
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Alibaba Group Holding Limited (BABA), and Netflix, Inc. (NFLX).
Vaccine Stocks Down Following Merck's COVID-19 Pill Success
by Kinjel Shah
Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19
Take a Look at the Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
Why Johnson & Johnson (JNJ) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Pharma Stock Roundup: MRK to Buy XLRN, ABBV Gets FDA Nod for Migraine Drug & More
by Kinjel Shah
Merck (MRK) offers to buy Acceleron Pharma for about $11.5 million. FDA approves AbbVie's (ABBV) new migraine drug, Qulipta.
Pfizer's (PFE) Prevnar 20 Plus Flu Vaccine Study Meets Goal
by Zacks Equity Research
Pfizer's (PFE) Prevnar 20 co-administered with a flu vaccine elicits non-inferior immunogenicity compared to administration of the vaccines one month apart in a late-stage study.
J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults
by Zacks Equity Research
J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.
Glaxo's (GSK) Long-Acting Drug NDA Gets Priority Tag for PrEP
by Zacks Equity Research
Glaxo's (GSK) HIV subsidiary, ViiV Healthcare gets FDA's priority review for a new drug application for long-acting cabotegravir regimen. ViiV Healthcare signs a deal for developing ultra long-acting HIV treatment.
Johnson & Johnson (JNJ) Stock Moves -0.22%: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $162.81, marking a -0.22% move from the previous day.
Pfizer (PFE) Begins COVID Prevention, mRNA Flu Vaccine Studies
by Zacks Equity Research
Pfizer (PFE) begins new studies on its oral antiviral pill for the prevention of COVID-19 infection and a potential mRNA influenza vaccine.
Acceleron (XLRN) Stock Up on Takeover Rumors for $11 Billion
by Zacks Equity Research
Acceleron (XLRN) up on rumors of a potential acquisition by a pharma giant for $11 billion or $180 per share.
AstraZeneca, Merck's Lynparza Prostate Cancer Study Meets Goal
by Zacks Equity Research
AstraZeneca (AZN) and Merck (MRK) announce that their PARP inhibitor Lynparza succeeds in meeting the primary endpoint in a late-stage study, evaluating it in first-line castration-resistant prostate cancer patients.
Pfizer (PFE) Booster Dose Gets CDC Backing for Older Adults Only
by Zacks Equity Research
The CDC recommends Pfizer (PFE)/ BioNTech's (BNTX) COVID-19 vaccine booster shots for older adults only but not for high-risk workers.
Pharma Stock Roundup: PFE Booster Jab Gets FDA Nod, JNJ's New Data on COVID-19 Shot
by Kinjel Shah
FDA grants EUA to Pfizer (PFE)/BioNTech's COVID-19 vaccine booster shots for limited use. J&J (JNJ) announces phase III data on booster dose of its single-shot vaccine.
J&J ETFs to Gain on Upbeat COVID-19 Vaccine Data
by Sweta Jaiswal, FRM
The positive data update has put the spotlight on a number of ETFs that could benefit from their high exposure to Johnson & Johnson.
Dynavax (DVAX) Gains on Clover's COVID-19 Vaccine Study Data
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Clover announces strong efficacy of its COVID-19 vaccine candidate against the Delta variant in pivotal study data readout.
Pfizer (PFE) Booster Dose Gets FDA Nod for High-Risk People
by Zacks Equity Research
FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Johnson & Johnson (JNJ) closed at $163.93, marking a -0.36% move from the previous day.
J&J's (JNJ) New Data Shows COVID-19 Booster Ups Protection
by Zacks Equity Research
J&J's (JNJ) data showed that a booster dose of its vaccine generated 94% efficacy against mild-to-severe COVID-19 in the United States. The data also confirmed that even one dose offers strong and long-lasting protection.